1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78.
3. Meng E, Lin WY, Lee WC, Chuang YC. Pathophysiology of overactive bladder. Low Urin Tract Symptoms 2012;4 Suppl 1:48-55.
4. Yoshimura N, Chancellor MB. Neurophysiology of lower urinary tract function and dysfunction. Rev Urol 2003;5 Suppl 8(Suppl 8):S3-10.
5. Puetz S, Lubomirov LT, Pfitzer G. Regulation of smooth muscle contraction by small GTPases. Physiology (Bethesda) 2009;24:342-56.
6. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996;273:245-8.
7. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 1996;271:20246-9.
8. Sharma P, Roy K. ROCK-2-selective targeting and its therapeutic outcomes. Drug Discov Today 2020;25:446-55.
9. Ferreira CE, Fonseca AM, Silva ID, Girão MJ, Sartori MG, Castro RA. The relationship between the Trp 64 Arg polymorphism of the beta 3-adrenoceptor gene and idiopathic overactive bladder. Am J Obstet Gynecol 2011;205:82.e10-4.
10. Gormley EA, Lightner DJ, Faraday M, Vasavada SP; American Urological Association; Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (nonneurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015;193:1572-80.
11. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000;55(5A Suppl):33-46.
13. Tarcan T, Mangır N, Ozgur O, Akbal C. OAB-V8 Asırı aktif mesane sorgulama formu validasyon calısmasi. Uroloji Bulteni 2012;21:113-6.
14. Fırat E, Aybek Z, Akgün Ş, Küçüker K, Akça H, Aybek H. Exploring biomarkers in the overactive bladder: Alterations in miRNA levels of a panel of genes in patients with OAB. Neurourol Urodyn 2019;38:1571-8.
15. Fırat E, Aybek Z, Akgün Ş, Küçüker K, Akça H, Aybek H. Relation of ADRB3, GEF, ROCK2 gene polymorphisms to clinical findings in overactive bladder. World J Urol 2020;38:2571-5.
19. Wang LW, Han XM, Chen CH, Ma Y, Hai B. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder. Int Urol Nephrol 2014;46:341-7.